GlaxoSmithKline (GSK) Stock Statistics & Valuation Metrics

GlaxoSmithKline has a market cap or net worth of £76.93B. The enterprise value is 99.27K .

GlaxoSmithKline has 4,045,395,300 shares outstanding. The number of shares has decreased by -2.65% in one year.

GlaxoSmithKline’s return on equity (ROE) is 0.35 and return on invested capital (ROIC) is 14.25%.

The current PE Ratio of GlaxoSmithKline is 13.2. GlaxoSmithKline’s PEG ratio is 0.10.

In the last 12 months, GlaxoSmithKline had revenue of 32.67B and earned 5.72B in profits. Earnings per share was 1.41.

In the last 12 months, operating cash flow was 7.55B and capital expenditures -2.53B, giving a free cash flow of 5.02B billion.

GlaxoSmithKline pays an annual dividend of 17 p, resulting in a dividend yield of 3.29%

GlaxoSmithKline upcoming earnings date is Jul 28, 2026, Before Open (Confirmed).

GlaxoSmithKline as a current ratio of 0.82, with Debt / Equity ratio of 106.74%

In the past 12 months, GlaxoSmithKline has paid 1.11B in taxes.

GlaxoSmithKline EV to EBITDA ratio is 7.45, with an EV/FCF ratio of 14.86.

GlaxoSmithKline has £3.44B in cash and marketable securities with £19.06B in debt, giving a net cash position of -£15.61B billion.

Gross margin is 72.74%, with operating margin of 21.95%, and net profit margin of 17.50%.

The average price target for GlaxoSmithKline is £2,103.00, which is 11.43% higher than the current price. The consensus rating is Hold